Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of HPG1860 in Healthy Subjects
NCT04480697Phase 1Completed
- Sponsor
- Hepagene Therapeutics
- Start
- Sep 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hpg1860 in Nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) (9 arms), sponsored by Hepagene Therapeutics. Primary endpoints: Number of subjects with treatment-emergent adverse events after single ascending doses and Number of subjects with treatment-emergent adverse events after multiple ascending doses. Started Sep 2019; status: completed.
02
Drugs
hpg1860
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04480697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480697.